FLUOROURACILUM
Consolidation
Hospital Alemão Oswaldo CruzSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Consolidation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Elranatamab University of Illinois at Chicago | Phase 2/3 | B |
Eloxatin Hospital Alemão Oswaldo Cruz | N/A | D |
Same molecule, other indications
FLUOROURACILUM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →